Related Experiment Video
Updated: Sep 10, 2025
Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
Hyperacmotone A alleviates Non-alcoholic Steatohepatitis via regulating PPARα signaling
Yueyou Yang1, Ping Ying2, Ziwei Jia1
1Jiangsu Key Laboratory of Bioactive Natural Product Research and State Key Laboratory of Natural Medicines, Shenzhen Research Institute of China Pharmaceutical University, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing 210009, PR China.
Background:
Non-alcoholic steatohepatitis (NASH) is a progressive form of non-alcoholic fatty liver disease (NAFLD), which is often accompanied by lipid metabolism disorders and mitochondrial dysfunction. Peroxisome proliferator-activated receptor α (PPARα) plays a crucial role in the oxidative metabolism of fatty acids, and its agonists are of great significance for the treatment of NASH.
Purpose:
This study mainly explored the anti-NASH effect of the natural product hyperacmotone A (HA) by targeting PPARα.
Method:
In this study, free fatty acids (FFA) were used in vitro to induce lipid deposition in hepatocytes, and a methionine and choline-deficient (MCD) diet was used in vivo to establish a NASH model in mice. The anti-NASH activity of HA and its therapeutic effect by targeting PPARα were comprehensively revealed through biochemical indices, pathological analysis, Western blotting, PCR, transcriptome sequencing analysis, DARTS, CETSA, molecular docking, molecular dynamics simulation, bio-layer interferometry assay, etc. RESULTS: The results of the study showed that HA reduced the lipid accumulation in L02, HepG2, AML12, and primary mouse hepatocytes (PMHs) induced by FFA. In the mouse model induced by the MCD diet, HA improved the histological lesions of NASH, including hepatic steatosis, liver injury, and fibrosis. The transcriptomic results indicated that the PPAR signaling pathway was one of the key pathways through which HA exerted its effects. The experiments further verified that HA directly bound to PPARα and activated downstream signaling, regulated lipid metabolism, and improved mitochondrial damage. Finally, it was confirmed that the anti-NASH effect of HA was dependent on the expression of PPARα.
Conclusion:
This study demonstrated that HA is a potential PPARα agonist and a therapeutic agent for NASH.
Related Concept Videos
01:24Phase II Reactions: Acetylation Reactions
The substrates for acetylation are typically drugs or their metabolites with an amino, sulfonamide, or hydrazine functional group. Acetylation can occur at several points in the drug molecule, including primary, secondary, and...
01:24Chronic Pancreatitis I: Introduction
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
01:27Acute Pancreatitis I: Introduction
Acute pancreatitis is characterized by rapid inflammation of the pancreas, often caused by factors like gallstone blockage or excessive alcohol consumption. Chronic pancreatitis, on the other hand, is a slow, progressive inflammation that may result from long-term alcohol abuse, obstructions in the pancreatic duct, or genetic factors.
The causes of acute pancreatitis include:
01:30Acute Pancreatitis II: Clinical Manifestations and Management
01:29Chronic Pancreatitis II: Collaborative Care
Assessment:
01:07Alkylation of β-Ketoester Enolates: Acetoacetic Ester Synthesis